What is non-invasive preimplantation genetic testing (niPGT)?

niPGT is a technique analyzing embryo DNA fragments released into culture medium, aiming to assess genetic health without embryo biopsy.

Why are Indian fertility societies cautioning against niPGT?

ISAR, IFS, and ACE caution against niPGT due to high misdiagnosis rates, with only 78% accuracy compared to traditional methods.

Can niPGT be used for embryo selection in India?

No, experts advise niPGT is not ready for routine clinical use and should not be used to select, rank, or discard embryos.

Home / Health / India Fertility Experts Caution Against New Embryo Screening

India Fertility Experts Caution Against New Embryo Screening

4 Jan

•

Summary

Non-invasive embryo testing shows high misdiagnosis rates.
Experts advise against using niPGT for routine clinical decisions.
Test matches conventional methods only 78% of the time.

India Fertility Experts Caution Against New Embryo Screening

Leading fertility and embryology organizations in India have issued a strong caution against the widespread clinical adoption of non-invasive preimplantation genetic testing (niPGT). The Indian Society for Assisted Reproduction (ISAR), Indian Fertility Society (IFS), and Academy of Clinical Embryologists (ACE) jointly reviewed available global data on niPGT. Their findings indicate that the test, which analyzes DNA fragments released by embryos without direct biopsy, exhibits high rates of misdiagnosis.

After reviewing data from nearly 3,000 embryos across 24 studies, the expert panel found that niPGT's accuracy aligns with conventional biopsy-based testing only about 78% of the time. This significant discrepancy means that genetically healthy embryos could be incorrectly flagged as abnormal, while others with abnormalities might be deemed normal. The review also found no convincing evidence that niPGT improves pregnancy outcomes or live birth rates.